Korro Bioの大手株主は3月10日に2300万ドルの株を買い,会社の四半期業績が悪いにもかかわらず,株価をほぼ19%増やしました. A major Korro Bio shareholder bought $2.3M in stock on March 10, boosting their stake by nearly 19%, despite the company's poor quarterly results.

2026年3月10日,Korro Bio (KRRO) の主要株主は,約230万ドルを費やして,それぞれ11.11ドルで207,100株を購入し,株式を18.99%増やして130万株に増加した. On March 10, 2026, a major shareholder of Korro Bio (KRRO) purchased 207,100 shares at $11.11 each, spending about $2.3 million and increasing their stake by 18.99% to 1.3 million shares. SECの提出で明らかにされた取引は,同社が予想より大幅に悪い,収益で1億2900万ドルで,四半期損失を1株当たり5.32ドルと報告したときに発生した. The transaction, disclosed in an SEC filing, occurred as the company reported a quarterly loss of $5.32 per share on $1.29 million in revenue, significantly worse than expected. 弱々しい財務結果にもかかわらず 内部情報の購入は信頼を示した Despite weak financial results, the insider buy signaled confidence. 株価は3月13日に11.50ドルで閉店し,0.26ドル下落し,市場キャピタルは10833万ドルで,P/E比率は負だった. The stock closed at $11.50 on March 13, down $0.26, with a market cap of $108.33 million and a negative P/E ratio. 分析官は平均50.38の目標を備えた"安定した評価"を掲げる. Analysts hold a "Hold" consensus rating with a $50.38 average target.